Nemaura Medical Inc. Stock

Equities

NMRD

US6404422080

Medical Equipment, Supplies & Distribution

Market Closed - OTC Markets 03:52:15 2024-05-17 pm EDT 5-day change 1st Jan Change
0.057 USD +26.67% Intraday chart for Nemaura Medical Inc. +83.28% -73.97%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 200K Sales 2025 * 1.4M Capitalization 2.3M
Net income 2024 * -9M Net income 2025 * -12M EV / Sales 2024 * 11.5 x
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * 1.64 x
P/E ratio 2024 *
-0.18 x
P/E ratio 2025 *
-0.13 x
Employees 36
Yield 2024 *
-
Yield 2025 *
-
Free-Float 51.38%
More Fundamentals * Assessed data
Dynamic Chart
1 day+26.67%
1 week+83.28%
Current month-4.84%
1 month-28.57%
3 months-31.33%
6 months-77.20%
Current year-73.97%
More quotes
1 week
0.03
Extreme 0.031
0.06
1 month
0.03
Extreme 0.0292
0.08
Current year
0.03
Extreme 0.0292
0.21
1 year
0.03
Extreme 0.0292
1.25
3 years
0.03
Extreme 0.0292
17.40
5 years
0.03
Extreme 0.0292
17.40
10 years
0.03
Extreme 0.0292
96.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 50 13-12-23
Chief Operating Officer 47 22-01-04
Chief Tech/Sci/R&D Officer 53 -
Members of the board TitleAgeSince
Chief Executive Officer 50 13-12-23
More insiders
Date Price Change Volume
24-05-17 0.057 +26.67% 252,056
24-05-16 0.045 +44.69% 119,121
24-05-15 0.0311 -6.61% 104,031
24-05-14 0.0333 +7.07% 49,040
24-05-13 0.0311 0.00% 134

Delayed Quote OTC Markets, May 17, 2024 at 03:52 pm EDT

More quotes
Nemaura Medical, Inc. is a medical technology company developing and commercializing non-invasive wearable diagnostic devices. The Company is commercializing sugarBEAT and proBEAT. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a continuous glucose monitoring system (CGM), sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and also be used to screen pre-diabetic patients. The sugarBEAT device extracts from analytes, such as glucose, from the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The SugarBEAT works by extracting glucose from the skin into a chamber in the patch that is in direct contact with an electrode-based sensor. The proBEAT combines non-invasive glucose data processed using artificial intelligence and a digital healthcare subscription service.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.057 USD
Average target price
1.5 USD
Spread / Average Target
+2,531.58%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW